Annual report pursuant to Section 13 and 15(d)

Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details)

v3.19.1
Acquisition of Pelican Therapeutics (Schedule of Pro Forma Financial Information for Acquisition) (Details)
$ / shares in Units, $ in Millions
12 Months Ended
Dec. 31, 2017
USD ($)
$ / shares
Business Combinations [Abstract]  
Grant and licensing revenue $ 1.5
Net loss (12.8)
Net loss: Non-controlling interest (0.6)
Net loss attributable to Heat Biologics, Inc. $ (12.2)
Net loss per share attributable to Heat Biologics, Inc.-basic and diluted | $ / shares $ (3.16)